{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:51:52Z","timestamp":1765039912858,"version":"3.44.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1176\/appi.psy.45.1.49","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T16:47:59Z","timestamp":1073407679000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Association Between Apolipoprotein E \u025b4 and Neuropsychiatric Symptoms During Interferon \u03b1 Treatment for Chronic Hepatitis C"],"prefix":"10.1016","volume":"45","author":[{"given":"Peter A.","family":"Gochee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth E.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Purdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmala","family":"Pandeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Shorthouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1176\/appi.psy.45.1.49_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","volume":"6","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1176\/appi.psy.45.1.49_bib0010","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.45.1.49_bib0015","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0020","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/jhep.2000.7880","article-title":"Hepatitis C, interferon alfa, and depression","volume":"31","author":"Zdilar","year":"2000","journal-title":"Hepatology"},{"key":"10.1176\/appi.psy.45.1.49_bib0030","first-page":"30","article-title":"Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes","volume":"25","author":"Licinio","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1176\/appi.psy.45.1.49_bib0035","first-page":"39","article-title":"Mood and cognitive side effects of interferon-alpha therapy","volume":"25","author":"Valentine","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1176\/appi.psy.45.1.49_bib0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(97)04318-3","article-title":"Association of apolipoprotein E polymorphism with outcome after head injury","volume":"350","author":"Teasdale","year":"1997","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.45.1.49_bib0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/07853890009011761","article-title":"Apolipoprotein E4: an allele associated with many diseases","volume":"32","author":"Smith","year":"2000","journal-title":"Ann Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0050","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1212\/WNL.55.10.1536","article-title":"Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation","volume":"55","author":"Lichtman","year":"2000","journal-title":"Neurology"},{"key":"10.1176\/appi.psy.45.1.49_bib0055","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00004647-199707000-00005","article-title":"Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia","volume":"17","author":"Laskowitz","year":"1997","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1176\/appi.psy.45.1.49_bib0060","first-page":"651","article-title":"Lower cognitive performance of older football players possessing apolipoprotein E epsilon4","volume":"47","author":"Kutner","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1176\/appi.psy.45.1.49_bib0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jama.1997.03550020068040","article-title":"Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing","volume":"278","author":"Jordan","year":"1997","journal-title":"JAMA"},{"key":"10.1176\/appi.psy.45.1.49_bib0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0197-4580(00)00097-X","article-title":"The role of apolipoprotein E in Alzheimer\u2019s disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models","volume":"21","author":"Horsburgh","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1176\/appi.psy.45.1.49_bib0075","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1073\/pnas.83.4.1130","article-title":"Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells","volume":"83","author":"Snipes","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1176\/appi.psy.45.1.49_bib0080","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.8171342","article-title":"Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro","volume":"264","author":"Nathan","year":"1994","journal-title":"Science"},{"key":"10.1176\/appi.psy.45.1.49_bib0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng0996-55","article-title":"Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides","volume":"14","author":"Miyata","year":"1996","journal-title":"Nat Genet"},{"key":"10.1176\/appi.psy.45.1.49_bib0090","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"10.1176\/appi.psy.45.1.49_bib0095","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/0140-6736(91)92823-K","article-title":"Apolipoprotein E genotyping by one-stage PCR","volume":"337","author":"Wenham","year":"1991","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.45.1.49_bib0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/clinchem\/41.2.187","article-title":"Improved PCR amplification\/Hhal restriction for unambiguous determination of apolipoprotein E alleles","volume":"41","author":"Appel","year":"1995","journal-title":"Clin Chem"},{"key":"10.1176\/appi.psy.45.1.49_bib0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/geno.1998.5454","volume":"52","author":"Gelernter","year":"1998","journal-title":"Genomics"},{"key":"10.1176\/appi.psy.45.1.49_bib0110","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/jhep.2002.34745","article-title":"Apolipoprotein E-\u025b4 protects against severe liver disease caused by hepatitis C virus","volume":"36","author":"Wozniak","year":"2002","journal-title":"Hepatology"},{"key":"10.1176\/appi.psy.45.1.49_bib0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/089198870101400303","article-title":"Apolipoprotein E epsilon 4 allele affects the relationship between stress and depression in caregivers of patients with Alzheimer\u2019s disease","volume":"14","author":"Gallagher-Thompson","year":"2001","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1176\/appi.psy.45.1.49_bib0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1176\/appi.psy.45.1.49_bib0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","article-title":"A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon","volume":"24","author":"Fattovich","year":"1996","journal-title":"J Hepatol"},{"key":"10.1176\/appi.psy.45.1.49_bib0130","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1002\/hep.510260720","article-title":"Side effects of alpha interferon in chronic hepatitis C","volume":"26","author":"Dusheiko","year":"1997","journal-title":"Hepatology"},{"key":"10.1176\/appi.psy.45.1.49_bib0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2008-1040523","article-title":"Side effects of alpha interferon","volume":"9","author":"Renault","year":"1989","journal-title":"Semin Liver Dis"},{"key":"10.1176\/appi.psy.45.1.49_bib0140","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.1987.00370090055011","article-title":"Psychiatric complications of long-term interferon alfa therapy","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.45.1.49_bib0150","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF00216072","article-title":"Effects of interferon alpha on performance in man: a preliminary report","volume":"96","author":"Smith","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1176\/appi.psy.45.1.49_bib0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/1097-0142(19910701)68:1<88::AID-CNCR2820680118>3.0.CO;2-5","article-title":"Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease","volume":"68","author":"Meyers","year":"1991","journal-title":"Cancer"},{"key":"10.1176\/appi.psy.45.1.49_bib0160","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jama.1984.03350070056026","article-title":"Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer","volume":"252","author":"Adams","year":"1984","journal-title":"JAMA"},{"key":"10.1176\/appi.psy.45.1.49_bib0165","first-page":"23","article-title":"The effects of interferon-alpha on the production and action of other cytokines","volume":"25","author":"Taylor","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1176\/appi.psy.45.1.49_bib0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1176\/appi.psy.45.1.49_bib0175","first-page":"165","article-title":"Free radicals and brain damage","volume":"1","author":"Siesjo","year":"1989","journal-title":"Cerebrovasc Brain Metab Rev"},{"key":"10.1176\/appi.psy.45.1.49_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(97)00029-5","article-title":"Is interferon-alpha a neuromodulator?","volume":"26","author":"Dafny","year":"1998","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1176\/appi.psy.45.1.49_bib0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0304-3940(95)11452-3","article-title":"Microglial localization of alpha-interferon receptor in human brain tissues","volume":"189","author":"Yamada","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1176\/appi.psy.45.1.49_bib0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0304-3940(94)90560-6","article-title":"Immunohistochemistry using antibodies to alpha-interferon and its induced protein, MxA, in Alzheimer\u2019s and Parkinson\u2019s disease brain tissues","volume":"181","author":"Yamada","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1176\/appi.psy.45.1.49_bib0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0014-2999(98)00187-3","article-title":"Effects of interferonalpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter","volume":"349","author":"Morikawa","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1176\/appi.psy.45.1.49_bib0200","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.psy.41.5.439","article-title":"Prophylactic treatment of depression induced by interferon-alpha","volume":"41","author":"Hauser","year":"2000","journal-title":"Psychosomatics"},{"key":"10.1176\/appi.psy.45.1.49_bib0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJM200108023450514","article-title":"Paroxetine for the prevention of depression induced by interferon alfa","volume":"345","author":"Kraus","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.5694\/j.1326-5377.2000.tb125687.x","article-title":"Sertraline treatment of interferon-alfa-induced depressive disorder","volume":"173","author":"Schramm","year":"2000","journal-title":"Med J Aust"},{"key":"10.1176\/appi.psy.45.1.49_bib0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/07357909509024923","article-title":"Treatment of neurotoxic side effects of interferon-alpha with naltrexone","volume":"13","author":"Valentine","year":"1995","journal-title":"Cancer Invest"},{"key":"10.1176\/appi.psy.45.1.49_bib0225","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0091-3057(96)00412-1","article-title":"Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury","volume":"56","author":"Lomnitski","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1176\/appi.psy.45.1.49_bib0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0925-4439(99)00010-1","article-title":"Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury","volume":"1453","author":"Lomnitski","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1176\/appi.psy.45.1.49_bib0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00004647-199804000-00003","article-title":"Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice","volume":"18","author":"Sheng","year":"1998","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1176\/appi.psy.45.1.49_bib0240","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1176\/appi.psy.45.1.49_bib0245","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/brain\/123.3.585","article-title":"The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson\u2019s disease","volume":"123","author":"Schiefermeier","year":"2000","journal-title":"Brain"},{"key":"10.1176\/appi.psy.45.1.49_bib0250","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0006-3223(98)00041-9","article-title":"Apolipoprotein E genotype and noncognitive symptoms in Alzheimer\u2019s disease","volume":"45","author":"Levy","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1176\/appi.psy.45.1.49_bib0255","first-page":"S27","article-title":"Behavioral changes associated with different apolipoprotein E genotypes in dementia","volume":"11","author":"Cacabelos","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1176\/appi.psy.45.1.49_bib0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/089198870101400303","article-title":"Apolipoprotein E epsilon4 allele affects the relationship between stress and depression in caregivers of patients with Alzheimer\u2019s disease","volume":"14","author":"Gallagher-Thompson","year":"2001","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1176\/appi.psy.45.1.49_bib0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1086\/303070","article-title":"Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism","volume":"67","author":"Fullerton","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1176\/appi.psy.45.1.49_bib0270","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jama.279.10.751","article-title":"The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics","volume":"279","author":"Tang","year":"1998","journal-title":"JAMA"},{"key":"10.1176\/appi.psy.45.1.49_bib0275","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(00)05270-3","article-title":"Evidence for a cerebral effect of the hepatitis C virus","volume":"358","author":"Forton","year":"2001","journal-title":"Lancet"},{"key":"10.1176\/appi.psy.45.1.49_bib0280","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0891-5849(99)00161-6","article-title":"Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic hepatitis C infection","volume":"27","author":"Farinati","year":"1999","journal-title":"Free Radic Biol Med"},{"key":"10.1176\/appi.psy.45.1.49_bib0285","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1073\/pnas.171311298","article-title":"Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B","volume":"98","author":"Gong","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1176\/appi.psy.45.1.49_bib0290","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0891-5849(97)00437-1","article-title":"Superoxide dismutase in patients with chronic hepatitis C virus infection","volume":"24","author":"Larrea","year":"1998","journal-title":"Free Radic Biol Med"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318204702194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318204702194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:25:44Z","timestamp":1758500744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318204702194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0033318204702194"],"URL":"https:\/\/doi.org\/10.1176\/appi.psy.45.1.49","relation":{},"ISSN":["0033-3182"],"issn-type":[{"type":"print","value":"0033-3182"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Apolipoprotein E \u025b4 and Neuropsychiatric Symptoms During Interferon \u03b1 Treatment for Chronic Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Psychosomatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1176\/appi.psy.45.1.49","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}